Tae-Hoon No

Dr. Tae-Hoon No

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2022 in Medicine
Verified
Journal Article
Open access
JLJae Ha Lee
Jae Ha Lee
SKSeong-Ho Kim
Seong-Ho Kim
JJJi Hoon Jang
Ji Hoon Jang
JPJin Han Park
Jin Han Park
KJKyung Min Jo
Kyung Min Jo
HLHyun Kyung Lee
Hyun Kyung Lee
Sepsis is a life-threatening condition and remains a major cause of mortality. The aim of this study was to evaluate the role of biomarkers in the diagnosis of sepsis and septic shock in patients admitted to the emergency department (ED). Medical records of patients who underwent measurement of serum biomarkers including lactic acid, C-reactive protein, procalcitonin (PCT), and presepsin in the ED between May 2019 and May 2020 were retrospectively reviewed. Patients were subdivided into 3 groups; non-sepsis, sepsis, and septic shock according to the new definition using the sequential organ failure assessment score. The mean age was 69.3 years, and 55.8% of the study population was female. Of 249 subjects, 98 patients confined to sepsis group, and 35.7% of them were septic shock. In the multivariable analysis, a high level of PCT was an independent predictor of sepsis (odds ratio [OR], 1.028; 95% confidence interval [CI], 1.006–1.051; P = .011) along with a simplified acute physiology score III (SAPS III) (OR, 1.082; 95% CI, 1.062–1.103, P < .001). PCT was also an independent risk factor for septic shock (OR, 1.043; 95% CI, 1.016–1.071, P = .02). In the receiver operating characteristic curve analysis, the area under the curve of PCT to predict sepsis and septic shock were 0.691 (P < .001) and 0.734 (P < .001), respectively. The overall 30-days mortality rate was 8.8%, and the mortality rate was significantly higher in the sepsis group (sepsis vs non-sepsis, 15.3% vs 4.6%; P = .004). In the multivariate Cox analysis, a higher level of lactic acid (hazard ratio [HR], 1.328; 95% CI, 1.061–1.663, P = .013), predisposing chronic pulmonary diseases (HR, 7.035; 95% CI, 1.687–29.341, P = .007), and a high SAPSIII value (HR, 1.046; 95% CI, 1.015–1.078, P = .003) were independent risk factors for mortality in sepsis patients. PCT was a useful biomarker for predicting sepsis and septic shock in the ED. A higher level of lactic acid, predisposing chronic pulmonary diseases, and a high SAPS III score were associated with a greater mortality risk in patients with sepsis.

1 January 2020 in Infection & Chemotherapy
Verified
Journal Article
Open access
PDF file
TNTae-Hoon No
Tae-Hoon No
KJKyeong Min Jo
Kyeong Min Jo
JYJung So Young
Jung So Young
MKMi Ra Kim
Mi Ra Kim
JKJooyeon Kim
Jooyeon Kim
Sung-Min KimSung-Min Kim
Sung-Min Kim
No TH, et al. Infect Chemother. 2020 Dec;52(4):634-640. https://doi.org/10.3947/ic.2020.52.4.634

17 August 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
KJKyeong Min Jo
Kyeong Min Jo
TNTae-Hoon No
Tae-Hoon No
Background: Antimicrobial stewardship programs (ASPs) are essential for promoting the rational use of antibiotics and combating resistance. In South Korea, implementation has recently accelerated, but real-world data on short-term program performance remain limited. This study evaluated the early outcomes of a newly launched ASP at a tertiary hospital. Methods: This retrospective, single-center study analyzed ASP activity from January to April 2025. Interventions included prospective audit and feedback for restricted antibiotics and recommendations for prolonged antibiotic prescriptions (≥14 days). The primary outcome was the monthly rejection rate of restricted antibiotics. Secondary outcomes included days of therapy (DOT) for restricted antibiotics and the acceptance rate of interventions for prolonged prescriptions. Results: The monthly rejection rate of restricted antibiotics remained stable between 3.65% and 4.68%. Although the DOT values did not show statistical significance, they demonstrated a moderate inverse correlation with the rejection rate (Pearson’s r = –0.868, p = 0.132). Among 826 prolonged prescriptions, 513 (62.1%) received ASP intervention. Acceptance of recommendations increased over time, from 67.0% in January to 82.5% in April. Interventions were primarily based on insufficient evidence of infection or inappropriate antibiotic selection. Conclusions: The newly implemented ASP demonstrated feasibility and early impact in improving antibiotic oversight. Despite the short observation period, the findings suggest a positive influence on prescribing practices. Longer-term studies are needed to evaluate sustained clinical outcomes and broader applicability in diverse healthcare settings.

17 October 2025 in Oncology Research and Treatment
Verified
Journal Article
Closed access
JCJae-Hyeog Choi
Jae-Hyeog Choi
SPSaegwang Park
Saegwang Park
XQXingguo Quan
Xingguo Quan
JPJin-Hee Park
Jin-Hee Park
MKMyoung Joo Kang
Myoung Joo Kang
IKIl Hwan Kim
Il Hwan Kim
Introduction: Myeloid-derived suppressor cells (MDSCs) constitute a heterogeneous population that plays a key role in tumor-related immune suppression. MDSCs are immature cells that express the myeloid markers CD11b and Gr1 in mice and accumulate in tumor-bearing mice, including those with HER2/neu+ breast cancer. We previously reported that tumor regression by anti-neu antibodies requires both innate and adaptive immunity. MDSCs inhibit both types of immunity and are immunosuppressive, particularly for T cells. However, the effect of anti-neu antibodies on MDSCs remains unclear. Methods: HER2+ TUBO tumor-bearing mice were treated with an anti-neu antibody or a control. MDSC populations were analyzed via flow cytometry, and immunosuppressive function was analyzed by a suppression assay. Tumors were analyzed using an RT2-PCR array and RT-PCR for gene expression related to MDSC activation, migration, and function. Additional mice received combination therapy with 5-FU or zoledronic acid to assess enhanced MDSC inhibition and changes in MDSC and tumor-associated macrophage (TAM) populations. Results: The number of MDSCs decreased within 3 days after anti-neu antibody treatment in the tumor and spleen, with the number of tumor MDSCs declining 1 day earlier. The number of monocytic MDSCs was significantly reduced in both tissues (p > 0.05). Anti-neu antibodies also reduced MDSC immunosuppressive activity. Gene expression analysis revealed decreased levels of IL-1β, VEGF, and CX3CL1, which are linked to MDSC activation and migration. The level of the immunosuppressive factor indoleamine 2,3-dioxygenase was also reduced. Compared with treatment with the antibody alone, combination therapy with 5-FU further suppressed the number of MDSCs and TAMs, resulting in better tumor suppression. Conclusions: Tumor suppression by anti-neu antibodies is associated with a reduction in MDSCs via the inhibition of key MDSC-related factors. MDSCs may be therapeutic targets for increasing Herceptin efficacy in patients with breast cancer.

22 May 2026 in Antibiotics
Verified
Journal Article
Open access
PDF file
TNTae-Hoon No
Tae-Hoon No
KJKyeong Min Jo
Kyeong Min Jo
Background: Antimicrobial stewardship programs (ASPs) are critical for promoting rational antibiotic use. While early implementation outcomes have been reported, extended follow-up sustainability and the impact on high-priority broad-spectrum antibiotics in South Korean secondary/tertiary hospitals require further validation. This study aimed to evaluate the extended outcomes and sustainability of an ASP over a 14-month period. Methods: This retrospective, single-center study analyzed ASP activities from January 2025 to February 2026 at a tertiary hospital in South Korea. Interventions included prospective audit and feedback (PAF) for restricted antibiotics and recommendations for prolonged prescriptions (≥14 days). Primary outcomes were the monthly rejection rate of restricted antibiotics and the acceptance rate of ASP interventions. Secondary outcomes included the days of therapy (DOT) per 1000 patient–days for meropenem and piperacillin/tazobactam (Pip/Taz). Results: During the 14-month period, the ASP intervention acceptance rate increased significantly from a mean of 72.0% in the implementation phase (January–April 2025) to 81.2% in the stabilization phase (May 2025–February 2026) (p = 0.035). The DOT for Pip/Taz decreased significantly from 169.4 to 151.8 per 1000 patient–days (p = 0.002), with a significant negative correlation identified between the intervention acceptance rate and Pip/Taz consumption (r = −0.625, p = 0.017). Although overall meropenem DOT showed seasonal fluctuations without reaching statistical significance across phases, a year-over-year comparison revealed a 7.5% reduction in meropenem DOT (January–February 2025: 54.8 vs. January–February 2026: 50.7 per 1000 patient–days). The rejection rate for restricted antibiotics declined from 3.8% to 2.6%, suggesting that clinicians increasingly self-regulated inappropriate prescribing attempts. Conclusions: The ASP demonstrated extended follow-up sustainability with a significant reduction in the consumption of key broad-spectrum antibiotics. A progressive increase in clinician acceptance of ASP interventions from 72.0% to 81.2%, combined with a concurrent decline in the restricted antibiotic rejection rate, reflected a measurable shift in institutional prescribing culture and confirmed the successful transition to a stabilized program. These findings support the necessity of sustained multidisciplinary ASPs, even in resource-limited settings, to combat antimicrobial resistance effectively.